Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need, PBD Biotech is announcing that it has appointed Dr Marie Roskrow to chair its board and has expanded its scientific advisory panel ahead of further trials.
  • January 17, 2023
  • Latest, People, Press release
  • human TB, staff
Marie Roskrow
Dr Marie Roskrow

Tuberculosis disease and deaths increased during the COVID-19 pandemic (www.who.int). This has created global demand for rapid tests such as Actiphage® (developed by PBD Biotech) to improve diagnosis of this preventable disease. In response to this need, PBD Biotech is announcing that it has appointed Dr Marie Roskrow to chair its board and has expanded its scientific advisory panel ahead of further trials.

Dr Roskrow is an experienced physician-scientist and senior executive. Her international experience in the healthcare and financial sectors includes roles as CEO, CMO and Chairperson in private and listed companies, including Patrys Ltd (Melbourne), Imevax (Munich), MetaLinear (UK), and Kinomica (UK). She is currently Chair of Arcticzymes Technologies (Norway).

Jane Theaker, CEO of PBD Biotech, comments: “We are delighted to bring Marie onboard. As an early-stage company, her experience of early and later-stage clinical development, relationships with investors, and extensive network of healthcare companies and clinical centres across Europe and the USA, will be invaluable to us.”

Dr Roskrow says she is looking forward to supporting the company in bringing Actiphage to market.

Actiphage is unique as it can detect live mycobacteria in a blood sample, providing an effective and non-invasive way to indicate that the patient has subclinical TB disease.

The World Health Organisation’s 2022 Global TB Report also said that the burden of drug-resistant TB (DR-TB) increased by 3% between 2020 and 2021, with 450 000 new cases of rifampicin-resistant TB (RR-TB) in 2021. This is the first time in many years that an increase has been reported in the number of people falling ill with TB and drug resistant TB.

Actiphage also has potential as a companion test for therapeutics and this is an area where Dr Roskrow has considerable knowledge. Her work at Imevax included development of a novel therapeutic vaccine and complementary rapid diagnostic test for the treatment of patients with resistant Helicobacter pylori. Her work is well-published, and she has earned many honours and awards.

PBD Biotech was originally focussed on diagnosis of mycobacterial diseases in animal health and benefited greatly from the expertise of Tom Green, PBD Biotech’s outgoing Chair. Tom will become a Non-Executive Director as the company prioritises human health.

Share:

Related posts

Loading...
pan North West of England’s Health and Life Sciences Cluster fight-against-infectious-disease

Phage-based diagnostics and the fight against infectious disease

May 22, 2023
PBD Biotech to speak at Liverpool School of Tropical Medicine anniversary celebrations
pan North West of England’s Health and Life Sciences Cluster fight-against-infectious-disease

Phage-based diagnostics and the fight against infectious disease

May 22, 2023
PBD Biotech to speak at Liverpool School of Tropical Medicine anniversary celebrations
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics

March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic tests that are urgently needed to screen LTBI and determine who will progress to active TB disease.
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics

March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic...
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis...
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic...
1 2 Next »

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!